Inventiva announces launch of public offering

Core Viewpoint - Inventiva plans to offer approximately $125 million (about €108 million) of new American Depositary Shares (ADSs) in an underwritten public offering in the United States, aimed at funding its clinical trials and commercialization activities [1][2]. Group 1: Offering Details - The offering will consist of new ADSs, each representing one ordinary share of the company with a nominal value of €0.01 [1]. - The net proceeds from the offering will primarily be used to fund the continuation of the NATiV3 Phase 3 clinical trial and other corporate purposes [2]. - The offering is subject to market conditions, and the final terms will be determined through a book-building process [4]. Group 2: Financial Information - As of September 30, 2025, the company had cash and cash equivalents of €97.6 million and short-term deposits of €24.7 million, which are projected to finance operations until the end of Q3 2026 [10]. - The company estimates that its current cash resources will not be sufficient to meet its obligations over the next 12 months [10]. Group 3: Regulatory and Market Considerations - The offering will be conducted without shareholders' preferential subscription rights, in accordance with resolutions from the company's general meeting [3]. - The ordinary shares represented by ADSs will be subject to an application for admission to trading on Euronext under the same ISIN code as existing shares [8]. - The trading of the company's ordinary shares on Euronext is expected to be suspended on November 13, 2025, until the opening of trading of the ADSs on Nasdaq [9]. Group 4: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [16]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH treatment [16].